VCP Scanner
Stock Screener
Filter stocks with fundamental & technical criteria
Market Themes
Curated industry baskets & thematic leaders
Earnings Hub
Calendar, EPS surprise stats & earnings transcripts
Market News
Real-time market intelligence & AI overviews
Insider Buying
SEC Form 4 corporate insider purchases
LearnAll lessons
Candlestick Patterns44 candles, each on two real charts
Pattern GuidesThe playbooks' setups on real breakouts
GlossaryInvesting terms in plain English
MinerviniVCP SetupsTrend Template
O'NeilCup with HandleFlat BaseDouble BottomCANSLIM Leaders
QullamaggieHigh Tight FlagsFlag BreakoutsEpisodic PivotsMomentum Leaders
KellWedge PopEMA Crossback
LivermorePivotal Points
PatternsFalling Wedge & ChannelBase Breakouts
View All Playbooks...
BreakoutsScanner
FAANG & Tech
AAPL vs MSFTNVDA vs AMDGOOGL vs META
Cloud & Cyber
CRM vs NOWCRWD vs PANWSNOW vs DDOG
Consumer & Auto
TSLA vs FAMZN vs WMTNFLX vs DIS
Finance & Crypto
JPM vs BACV vs MACOIN vs MSTR
Index & ETFs
SPY vs QQQVTI vs VOOSPY vs IWM
Compare Any Stocks...
DCF ValuationCalculate intrinsic value of US stocks
Market ValuationBuffett indicator, CAPE & macro gauges
Total ReturnSee dividends + price return history
DCA CalculatorSimulate recurring buys & compounding
VisualizeInteractive multi-year financial charts
Watchlist
BreakoutsScanner
WatchlistPricing
Ctrl K
Pricing
ALXO
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Analyze deeply. Research with clarity.

Data updated daily

Product

  • Screener
  • Scanner
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • Pricing
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly market insights — free

© 2026 VCP Scanner
AboutPrivacyTermsRefund Policy
Not financial advice. Do your own research.
ScreenerBreakoutsScannerWatchlist
ALXOALX Oncology Holdings Inc.
$0.97$131M
Overview & Tools
OverviewChart Terminal ↗Visualize
Valuation & Forecasts
Valuation ModelsEstimatesDCF Model
Price & Analyst Data
Analyst TargetsPrice History
Financial Statements
Income StatementBalance SheetCash FlowRatios & Margins
Performance
P/E HistoryRevenue HistoryEarnings HistoryDividend HistoryTotal Return
Discovery & Screens
Live BreakoutsStock ScreenerOwnership
HomeStocksALXOBalance Sheet

ALX Oncology Holdings Inc. (ALXO) Balance Sheet

8Y historyFree accessUpdated daily

Total debt declined to $9.7M in 2026Q2 with a debt-to-equity ratio of 0.07, but cash of $22.7M and an accumulated deficit of $758.7M indicate the capital structure is funded almost entirely by equity issuance.

Income StatementBalance SheetCash FlowRatios

ALXO Balance Sheet

Annual statement

ALXO Balance Sheet

ALX Oncology Holdings Inc. (ALXO) balance sheet — 8-year assets, liabilities & shareholders' equity history

AnnualQuarterly
MetricTTMDec'25Dec'24Dec'23Dec'22Dec'21Dec'20Dec'19Dec'18
Total Current Assets152.87M50.73M134.35M188.66M270.97M367.02M435.99M9.81M10.21M
Cash & Short-Term Investments147.21M44.79M127.76M182.74M266.21M363.67M434.22M9.02M8.26M
Cash Only35.45M16.37M17.57M22.41M48.82M363.67M434.22M9.02M8.26M
Short-Term Investments111.75M28.42M110.19M160.33M217.38M0000
Accounts Receivable0298K892K0000536K932K
Days Sales Outstanding-------40.79164.58
Inventory000000000
Days Inventory Outstanding---------
Other Current Assets5.66M5.64M5.7M5.92M4.76M0000
Total Non-Current Assets1.8M8.32M13.42M53.89M35.52M13.16M62K867K956K
Property, Plant & Equipment149K1.2M9.63M10.84M9.81M3.47M52K860K956K
Fixed Asset Turnover0.00x-----22.73x5.58x2.16x
Goodwill000000000
Intangible Assets000000000
Long-Term Investments47.42M3.49M3.52M35.41M16.7M0000
Other Non-Current Assets1.66M3.63M267K7.64M9.01M9.69M10K7K0
Total Assets154.67M59.05M147.78M242.55M306.49M380.18M436.05M10.68M11.16M
Asset Turnover0.00x-----0.00x0.45x0.19x
Asset Growth %143.15%-60.04%-39.08%-20.86%-19.38%-12.81%3984.43%-4.37%-
Total Current Liabilities19.02M24.55M18.5M36M28.32M15.29M6.2M4.98M1.87M
Accounts Payable3.99M4.91M4.5M8.59M8.07M3.76M4K3.75M697K
Days Payables Outstanding9.6K-----1.36313.77135.32
Short-Term Debt05.22M435K000000
Deferred Revenue (Current)000000000
Other Current Liabilities19.02M14.42M5.97M6.7M4.72M3.53M2.13M1.06M369K
Current Ratio8.04x2.07x7.26x5.24x9.57x24.00x70.28x1.97x5.45x
Quick Ratio8.04x2.07x7.26x5.24x9.57x24.00x70.28x1.97x5.45x
Cash Conversion Cycle---------
Total Non-Current Liabilities9.8M8.51M15.66M16.84M14.7M1.84M5K5.97M136K
Long-Term Debt009.47M9.64M9.39M005.42M0
Capital Lease Obligations005.16M5.98M00000
Deferred Tax Liabilities000000000
Other Non-Current Liabilities9.8M8.51M1.03M1.22M5.31M1.84M5K412K0
Total Liabilities28.82M33.06M34.16M52.84M43.02M17.13M6.21M10.95M2.01M
Total Debt05.22M16.98M17.2M10.43M742K05.42M0
Net Debt-35.45M-11.16M-589K-5.21M-38.39M-362.93M-434.22M-3.6M-8.26M
Debt / Equity0.00x0.20x0.15x0.09x0.04x0.00x---
Debt / EBITDA-0.00x--------
Net Debt / EBITDA0.43x--------
Interest Coverage-74.61x-62.48x-76.99x-101.75x-517.56x-6420.85x-53.84x-913.71x-
Total Equity125.85M25.98M113.62M189.71M263.46M363.05M429.85M-276K9.15M
Equity Growth %286.62%-77.13%-40.11%-27.99%-27.43%-15.54%--103.01%-
Book Value per Share0.890.482.184.416.479.0110.79-0.010.42
Total Shareholders' Equity125.85M25.98M113.62M189.71M263.46M363.05M429.85M-276K9.15M
Common Stock143K54K53K50K41K41K40K3K3K
Retained Earnings-780.54M-722.82M-621.12M-486.27M-325.47M-201.99M-118.52M-72.78M-53.54M
Treasury Stock000000000
Accumulated OCI-259K28K275K256K-845K000-1.02M
Minority Interest000000000

Key Metrics

Growth RegimeMixed
ProfitabilityNegative
Balance SheetMixed
Cash FlowBurning
Top Statement Risk

Dependence on external capital markets

Verified Source

Metrics are mathematically derived from official filings.

SEC 10-K (2026Q2)

Equity Eroded by Accumulated Losses

According to ALXO's reported balance sheets, total assets swung from $212.7M in 2024Q1 to $160.8M in 2026Q2 while accumulated deficit deepened to $758.7M, indicating a balance sheet being consumed by sustained operating losses over the period.

The reported figures suggest the balance sheet is weakening in aggregate, with the accumulated deficit growing every quarter while asset levels have trended lower. The apparent rebound in assets during 2026Q1 appears linked to a financing inflow rather than operating strength, which warrants further investigation through the cash flow statement. Investors should monitor whether the current cash base supports the program timeline without another raise.

Cash Buffer Thin Against Burn Rate

Based on reported figures, ALXO held $22.7M in cash at 2026Q2 against free cash flow of roughly -$34.8M in the same quarter, suggesting the existing liquidity cushion covers less than one quarter of cash consumption.

The current ratio of 9.71 looks strong on the surface, but it reflects a small liability base rather than a large cash reserve, so the ratio overstates true resilience. Cash of $22.7M against quarterly burn near $35M implies the company likely needs external capital in the near term. The reported figures do not disclose financing commitments, so the adequacy of runway remains an open question for analysts to assess.

Negligible Leverage, Equity-Funded Model

As reported in financial statements, ALXO's total debt fell to $9.7M in 2026Q2 with a debt-to-equity ratio of 0.07, indicating the company is financed almost entirely by equity rather than borrowing.

Low leverage means debt service is not a constraint on cash flow, which is a relative positive given the burn profile. The low debt level instead shifts the risk toward equity dilution, since the business depends on share issuance to fund operations. Investors should treat the balance sheet's apparent lack of leverage as a function of the funding model rather than evidence of financial strength.

Equity Base Dependent on Issuance

Based on ALXO's reported figures, shareholders' equity rose to $136.2M in 2026Q2 from $26.0M in 2025Q4 while retained earnings remained deeply negative, pointing to equity replenishment through capital raises rather than earnings.

The sharp equity increase during 2026 is inconsistent with any earnings contribution, given the persistent accumulated deficit, and suggests dilutive issuance funded the recent asset base. Stock-based compensation further adds to share-count pressure over time. Analysts should evaluate per-share value creation against the continued issuance pattern implied by the reported equity trajectory.

Low Leverage Masks Funding Risk

The headline debt-to-equity ratio of 0.07 may look reassuring, but reported figures suggest the company's real constraint is its reliance on external equity funding to offset a cumulative operating loss exceeding $200M.

A clean debt profile can understate risk when the business has no reported revenue base to service obligations or fund operations internally. The absence of borrowing is a function of the equity-funded model and does not imply durable self-sufficiency. This reading suggests investors should weigh the dilution exposure more heavily than the leverage metrics alone.

ALXO — Frequently Asked Questions

Quick answers to the most common questions about buying ALXO stock.

What are the total assets of ALX Oncology Holdings Inc. (ALXO)?

As of 2025, ALX Oncology Holdings Inc. (ALXO) had total assets of $59.0M including $50.7M in current assets.

How much debt does ALX Oncology Holdings Inc. (ALXO) have?

ALX Oncology Holdings Inc. (ALXO) carries total debt of $5.2M, offset by $44.8M in cash and short-term investments. Comparing total debt to cash helps evaluate the company's debt burden and net leverage.

What is the book value or shareholders' equity of ALX Oncology Holdings Inc.?

ALX Oncology Holdings Inc. (ALXO) has total shareholders' equity (book value) of $26.0M ($0.48 book value per share). Book value represents the net worth of the company belonging to common stock holders.

What is ALX Oncology Holdings Inc.'s current ratio and liquidity?

ALX Oncology Holdings Inc. (ALXO) reported a current ratio of 2.07x. A current ratio above 1.0x indicates that the company has more current assets than current liabilities, suggesting sufficient short-term liquidity.